S&P 500   4,094.18 (+1.07%)
DOW   33,165.68 (+0.93%)
QQQ   319.57 (+1.23%)
AAPL   164.24 (+1.16%)
MSFT   287.21 (+1.11%)
META   210.29 (+1.18%)
GOOGL   102.94 (+2.03%)
AMZN   102.84 (+0.82%)
TSLA   207.08 (+6.04%)
NVDA   276.25 (+0.88%)
NIO   10.48 (+0.19%)
BABA   102.24 (-1.10%)
AMD   97.76 (-0.12%)
T   19.17 (+0.47%)
F   12.42 (+1.06%)
MU   60.78 (-3.66%)
CGC   1.76 (-0.28%)
GE   95.22 (+1.24%)
DIS   99.52 (+1.45%)
AMC   4.99 (+0.40%)
PFE   40.34 (-0.10%)
PYPL   75.29 (+1.21%)
NFLX   344.10 (+1.68%)
S&P 500   4,094.18 (+1.07%)
DOW   33,165.68 (+0.93%)
QQQ   319.57 (+1.23%)
AAPL   164.24 (+1.16%)
MSFT   287.21 (+1.11%)
META   210.29 (+1.18%)
GOOGL   102.94 (+2.03%)
AMZN   102.84 (+0.82%)
TSLA   207.08 (+6.04%)
NVDA   276.25 (+0.88%)
NIO   10.48 (+0.19%)
BABA   102.24 (-1.10%)
AMD   97.76 (-0.12%)
T   19.17 (+0.47%)
F   12.42 (+1.06%)
MU   60.78 (-3.66%)
CGC   1.76 (-0.28%)
GE   95.22 (+1.24%)
DIS   99.52 (+1.45%)
AMC   4.99 (+0.40%)
PFE   40.34 (-0.10%)
PYPL   75.29 (+1.21%)
NFLX   344.10 (+1.68%)
S&P 500   4,094.18 (+1.07%)
DOW   33,165.68 (+0.93%)
QQQ   319.57 (+1.23%)
AAPL   164.24 (+1.16%)
MSFT   287.21 (+1.11%)
META   210.29 (+1.18%)
GOOGL   102.94 (+2.03%)
AMZN   102.84 (+0.82%)
TSLA   207.08 (+6.04%)
NVDA   276.25 (+0.88%)
NIO   10.48 (+0.19%)
BABA   102.24 (-1.10%)
AMD   97.76 (-0.12%)
T   19.17 (+0.47%)
F   12.42 (+1.06%)
MU   60.78 (-3.66%)
CGC   1.76 (-0.28%)
GE   95.22 (+1.24%)
DIS   99.52 (+1.45%)
AMC   4.99 (+0.40%)
PFE   40.34 (-0.10%)
PYPL   75.29 (+1.21%)
NFLX   344.10 (+1.68%)
S&P 500   4,094.18 (+1.07%)
DOW   33,165.68 (+0.93%)
QQQ   319.57 (+1.23%)
AAPL   164.24 (+1.16%)
MSFT   287.21 (+1.11%)
META   210.29 (+1.18%)
GOOGL   102.94 (+2.03%)
AMZN   102.84 (+0.82%)
TSLA   207.08 (+6.04%)
NVDA   276.25 (+0.88%)
NIO   10.48 (+0.19%)
BABA   102.24 (-1.10%)
AMD   97.76 (-0.12%)
T   19.17 (+0.47%)
F   12.42 (+1.06%)
MU   60.78 (-3.66%)
CGC   1.76 (-0.28%)
GE   95.22 (+1.24%)
DIS   99.52 (+1.45%)
AMC   4.99 (+0.40%)
PFE   40.34 (-0.10%)
PYPL   75.29 (+1.21%)
NFLX   344.10 (+1.68%)
NASDAQ:HALO

Halozyme Therapeutics - HALO Stock Forecast, Price & News

$38.14
+0.83 (+2.22%)
(As of 03/31/2023 02:59 PM ET)
Add
Compare
Today's Range
$37.45
▼
$38.28
50-Day Range
$32.86
▼
$53.28
52-Week Range
$32.83
▼
$59.46
Volume
606,515 shs
Average Volume
1.59 million shs
Market Capitalization
$5.16 billion
P/E Ratio
26.30
Dividend Yield
N/A
Price Target
$56.33

Halozyme Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
48.0% Upside
$56.33 Price Target
Short Interest
Healthy
4.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.73mentions of Halozyme Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$4.55 M Sold Last Quarter
Proj. Earnings Growth
47.72%
From $2.41 to $3.56 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.50 out of 5 stars

Medical Sector

4th out of 1,009 stocks

Biological Products, Except Diagnostic Industry

2nd out of 166 stocks

See Top Rated MarketRank™ Stocks Here

HALO stock logo

About Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Stock News Headlines

March 30, 2023 | marketwatch.com
Hyaluronidase Market Analysis Report | 2023-2029
March 29, 2023 | americanbankingnews.com
Halozyme Therapeutics (NASDAQ:HALO) Stock Price Up 4.9%
March 31, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
March 29, 2023 | americanbankingnews.com
Berenberg Bank Initiates Coverage on Halozyme Therapeutics (NASDAQ:HALO)
March 23, 2023 | finance.yahoo.com
Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?
March 22, 2023 | americanbankingnews.com
Halozyme Therapeutics, Inc. to Post Q3 2023 Earnings of $0.66 Per Share, SVB Leerink Forecasts (NASDAQ:HALO)
March 21, 2023 | finance.yahoo.com
Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?
March 18, 2023 | benzinga.com
SVB Leerink Downgrades Halozyme Therapeutics to Market Perform, Announces $42 Price Target
March 31, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 16, 2023 | msn.com
SVB Leerink Downgrades Halozyme Therapeutics (HALO)
March 16, 2023 | msn.com
The Latest Analyst Ratings for Halozyme Therapeutics
March 16, 2023 | finance.yahoo.com
Dow Jones Rises Even As Fed's Pivot Remains Uncertain; Health Care Stocks Fall On New Medicare Plan
March 15, 2023 | marketwatch.com
Global Hyaluronidase Market Size by Application (Dermatology, Plastic Surgery) Forecast from 2023 to 2028
March 15, 2023 | msn.com
Halozyme sees no impact on royalties after EU body revokes J&J's Darzalex patent
March 15, 2023 | finance.yahoo.com
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
March 14, 2023 | benzinga.com
Halozyme Therapeutics Stock (NASDAQ:HALO), Guidance and Forecast
March 13, 2023 | benzinga.com
Halozyme Therapeutics Stock (NASDAQ:HALO), Analyst Ratings, Price Targets, Predictions
March 13, 2023 | finance.yahoo.com
Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options
March 10, 2023 | marketwatch.com
Antidiabetic Drug Market to 2023-2028
February 26, 2023 | seekingalpha.com
Halozyme Therapeutics: A Trailblazer, But With Lukewarm Financials
February 25, 2023 | benzinga.com
JP Morgan Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $52
February 23, 2023 | benzinga.com
Halozyme Therapeutics Q4 EPS $0.42 Misses $0.47 Estimate, Sales $181.50M Miss $192.05M Estimate
February 21, 2023 | finance.yahoo.com
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
February 15, 2023 | 247wallst.com
BlackRock Increases Position in Halozyme Therapeutics
February 10, 2023 | finance.yahoo.com
Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?
February 6, 2023 | finance.yahoo.com
Halozyme Appoints Barbara Duncan to its Board of Directors
January 30, 2023 | marketwatch.com
Hyaluronidase Market Size in 2023 Industry Demand, Industry News, Business Growth, Top Key Players Update till 2028
See More Headlines
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Company Calendar

Last Earnings
11/02/2021
Today
3/31/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:HALO
CUSIP
40637H10
CIK
1159036
Web
www.halozyme.com
Phone
858-794-8889
Fax
858-704-8311
Employees
145
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$56.33
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+51.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$1.45
Trailing P/E Ratio
25.73
Forward P/E Ratio
15.48
P/E Growth
0.54
Net Income
$202.13 million
Net Margins
30.62%
Pretax Margin
37.71%
Return on Equity
141.30%
Return on Assets
17.43%

Debt

Debt-to-Equity Ratio
8.79
Current Ratio
5.65
Quick Ratio
4.88

Sales & Book Value

Annual Sales
$660.12 million
Price / Sales
7.65
Cash Flow
$2.65 per share
Price / Cash Flow
14.08
Book Value
$1.26 per share
Price / Book
29.61

Miscellaneous

Outstanding Shares
135,410,000
Free Float
132,300,000
Market Cap
$5.05 billion
Optionable
Optionable
Beta
1.26

Social Links


Key Executives

  • Dr. Helen I. Torley M.B. Ch. B. (Age 59)
    M.R.C.P., Pres, CEO & Director
    Comp: $1.65M
  • Dr. Michael J. LaBarre Ph.D. (Age 58)
    Chief Technical Officer
    Comp: $779.55k
  • Ms. Nicole LaBrosse (Age 39)
    CFO & Director
  • Ms. Tram Bui
    VP of Investor Relations & Corp. Communications
  • Mr. Mark Snyder Esq.
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Ms. Amy Marinne Fox
    Chief HR Officer
  • Dr. Steve Knowles MBBS
    Chief Medical Officer
  • Mr. Todd Butler
    Chief of Staff to the CEO, VP & Head of Project Management
  • Dr. Christopher Bryant Ph.D. (Age 61)
    Chief Manufacturing Officer & Head of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













HALO Stock - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HALO shares.
View HALO analyst ratings or view top-rated stocks.

What is Halozyme Therapeutics' stock price forecast for 2023?

9 equities research analysts have issued 12-month target prices for Halozyme Therapeutics' shares. Their HALO share price forecasts range from $42.00 to $68.00. On average, they anticipate the company's share price to reach $56.33 in the next year. This suggests a possible upside of 49.9% from the stock's current price.
View analysts price targets for HALO or view top-rated stocks among Wall Street analysts.

How have HALO shares performed in 2023?

Halozyme Therapeutics' stock was trading at $56.90 at the start of the year. Since then, HALO stock has decreased by 33.9% and is now trading at $37.59.
View the best growth stocks for 2023 here.

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our HALO earnings forecast.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $1.06. The biopharmaceutical company earned $115.83 million during the quarter, compared to analysts' expectations of $101.94 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 141.30% and a net margin of 30.62%. During the same quarter last year, the company earned $0.25 EPS.

What ETFs hold Halozyme Therapeutics' stock?

ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include Future Fund Active ETF (FFND), Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco DWA Healthcare Momentum ETF (PTH), Goldman Sachs Future Health Care Equity ETF (GDOC), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Invesco S&P MidCap 400 Pure Growth ETF (RFG) and WisdomTree U.S. Growth & Momentum Fund (WGRO).

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics updated its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided earnings per share (EPS) guidance of $2.50-$2.65 for the period, compared to the consensus earnings per share estimate of $2.78. The company issued revenue guidance of $815.00 million-$845.00 million, compared to the consensus revenue estimate of $868.12 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (5.28%), William Blair Investment Management LLC (2.74%), Macquarie Group Ltd. (1.93%), Geode Capital Management LLC (1.86%), GW&K Investment Management LLC (1.54%) and Price T Rowe Associates Inc. MD (1.21%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $37.59.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $5.09 billion and generates $660.12 million in revenue each year. The biopharmaceutical company earns $202.13 million in net income (profit) each year or $1.45 on an earnings per share basis.

How many employees does Halozyme Therapeutics have?

The company employs 145 workers across the globe.

Does Halozyme Therapeutics have any subsidiaries?
The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.

This page (NASDAQ:HALO) was last updated on 3/31/2023 by MarketBeat.com Staff